TSH-secreting pituitary adenomas
- Roy E Weiss, MD, PhD
Roy E Weiss, MD, PhD
- Professor and Chairman
- The University of Miami Miller School of Medicine
- Samuel Refetoff, MD
Samuel Refetoff, MD
- Professor of Medicine, Pediatrics, and Committee on Genetics
- University of Chicago
Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas are a rare cause of hyperthyroidism . They account for 0.5 to 3 percent of all functioning pituitary tumors  and much less than 1 percent of all cases of hyperthyroidism. The incidence in Sweden is calculated to be 2.8 per 1 million, in which 0.85 per million had disease . Nevertheless, the diagnosis should be considered in all hyperthyroid patients, especially those with a diffuse goiter and no extrathyroidal manifestations of Graves' disease.
This topic will review the clinical presentation, diagnosis, and treatment of TSH-secreting pituitary tumors. Other causes of hyperthyroidism are reviewed separately. (See "Disorders that cause hyperthyroidism" and "Diagnosis of hyperthyroidism".)
TSH-secreting adenomas secrete biologically active TSH in a more or less autonomous fashion. Thus, TSH secretion usually does not increase much in response to thyrotropin-releasing hormone (TRH) and does not decrease much in response to exogenous thyroid hormone administration. The biological activity of the TSH that is secreted varies considerably; as a result, serum immunoreactive TSH concentrations range from normal (albeit inappropriately high in the presence of hyperthyroidism) to markedly elevated (>500 mU/L) .
Most TSH-secreting adenomas secrete only TSH. However, approximately 20 to 25 percent of the adenomas secrete one or more other pituitary hormones, predominantly growth hormone or prolactin . There have been no reported instances of co-secretion of corticotropin (ACTH) and TSH.
Adenomas secreting TSH and growth hormone are equally common in men and women, whereas co-secretion of TSH and prolactin is approximately five times more common in women than in men. Hyperprolactinemia is not always due to tumor secretion of prolactin; in some patients, it is caused by compression of the pituitary stalk and interruption of tonic hypothalamic inhibition of prolactin secretion. (See "Causes of hyperprolactinemia", section on 'Decreased dopaminergic inhibition of prolactin secretion'.)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Ónnestam L, Berinder K, Burman P, et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 2013; 98:626.
- Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2013; 2:76.
- Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17:610.
- Delhase M, Vergani P, Malur A, et al. Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. J Mol Endocrinol 1993; 11:129.
- Sanno N, Teramoto A, Matsuno A, et al. Clinical and immunohistochemical studies on TSH-secreting pituitary adenoma: its multihormonality and expression of Pit-1. Mod Pathol 1994; 7:893.
- Pellegrini I, Barlier A, Gunz G, et al. Pit-1 gene expression in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 1994; 79:189.
- Ando S, Sarlis NJ, Krishnan J, et al. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 2001; 15:1529.
- Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001; 86:5572.
- Tagami T, Usui T, Shimatsu A, et al. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J Clin Endocrinol Metab 2011; 96:E948.
- Dong Q, Brucker-Davis F, Weintraub BD, et al. Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab 1996; 81:1134.
- Brucker-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999; 84:476.
- Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003; 148:433.
- Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23:597.
- Perticone F, Pigliaru F, Mariotti S, et al. Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series. Thyroid 2015; 25:417.
- Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves' disease: a case report. J Med Case Rep 2013; 7:27.
- Kamoun M, d'Herbomez M, Lemaire C, et al. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves' hyperthyroidism. Eur Thyroid J 2014; 3:60.
- Beckers A, Abs R, Mahler C, et al. Thyrotropin-secreting pituitary adenomas: report of seven cases. J Clin Endocrinol Metab 1991; 72:477.
- Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14:348.
- Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary adenomas. Trends Endocrinol Metab 1992; 3:41.
- Clarke MJ, Erickson D, Castro MR, Atkinson JL. Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 2008; 109:17.
- Okuyucu K, Alagoz E, Arslan N, et al. Thyrotropinoma with Graves' disease detected by the fusion of indium-111 octreotide scintigraphy and pituitary magnetic resonance imaging. Indian J Nucl Med 2016; 31:141.
- Després N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem 1998; 44:440.
- Sakai H, Fukuda G, Suzuki N, et al. Falsely elevated thyroid-stimulating hormone (TSH) level due to macro-TSH. Endocr J 2009; 56:435.
- Verhoye E, Van den Bruel A, Delanghe JR, et al. Spuriously high thyrotropin values due to anti-thyrotropin antibodies in adult patients. Clin Chem Lab Med 2009; 47:604.
- Mills F, Jeffery J, Mackenzie P, et al. An immunoglobulin G complexed form of thyroid-stimulating hormone (macro thyroid-stimulating hormone) is a cause of elevated serum thyroid-stimulating hormone concentration. Ann Clin Biochem 2013; 50:416.
- Bogazzi F, Manetti L, Tomisti L, et al. Thyroid color flow Doppler sonography: an adjunctive tool for differentiating patients with inappropriate thyrotropin (TSH) secretion due to TSH-secreting pituitary adenoma or resistance to thyroid hormone. Thyroid 2006; 16:989.
- Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.
- Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12:450.
- Cooper DS, Wenig BM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid 1996; 6:337.
- Song M, Wang H, Song L, et al. Ectopic TSH-secreting pituitary tumor: a case report and review of prior cases. BMC Cancer 2014; 14:544.
- Pasquini E, Faustini-Fustini M, Sciarretta V, et al. Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur J Endocrinol 2003; 148:253.
- Fukuhara N, Horiguchi K, Nishioka H, et al. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J 2015; 62:21.
- Rimareix F, Grunenwald S, Vezzosi D, et al. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients. Thyroid 2015; 25:877.
- Fliers E, van Furth WR, Bisschop PH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol (Oxf) 2012; 77:788.
- Yoshihara A, Isozaki O, Hizuka N, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J 2007; 54:133.
- Horiguchi K, Yamada M, Umezawa R, et al. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J 2007; 54:371.
- Mulinda JR, Hasinski S, Rose LI. Successful therapy for a mixed thyrotropin-and prolactin-secreting pituitary macroadenoma with cabergoline. Endocr Pract 1999; 5:76.
- Camacho P, Mazzone T. Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy. Endocr Pract 1999; 5:257.
- Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol 2007; 157:39.
- Losa M, Giovanelli M, Persani L, et al. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81:3084.
- Gatto F, Grasso LF, Nazzari E, et al. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? Pituitary 2015; 18:583.
- Malchiodi E, Profka E, Ferrante E, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 2014; 99:2069.
- Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000; 85:1487.
- Brown RL, Muzzafar T, Wollman R, Weiss RE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol 2006; 154:639.
- CLINICAL PRESENTATION
- Symptoms and signs
- Thyroid function tests
- Alpha subunit
- Imaging studies
- Differential diagnosis
- - Assay interference
- - Resistance to thyroid hormone
- - Long-standing primary hypothyroidism
- Diagnostic evaluation
- - Medical therapy
- Restore euthyroidism prior to neurosurgery
- Reduce tumor size prior to neurosurgery
- Primary treatment
- - Surgery
- Criteria for cure
- Residual disease
- - Somatostatin analogs
- - Pituitary irradiation
- - Thyroidectomy
- Long-term monitoring
- SUMMARY AND RECOMMENDATIONS